Abstract
Pancreatic ductal adenocarcinoma is an aggressive tumor with poor prognosis and survival. Surgery is a treatment of choice for this tumors. Potentially resectable tumors are now treated with neoadjuvant therapy. This leads to necessity for pathologist to score the tumor response to neoadjuvant therapy. To date the international agreement guides for pathologic assessment of pancreatectomy specimens after neoadjuvant therapy are lack. Here we review the data on grossing and microscopic study of pancreatic ductal adenocarcinoma after neoadjuvant therapy, as well as data regarding the prognostic significance of tumor staging, therapy response and other pathologic parameters.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
